SG10201600531TA - Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins - Google Patents

Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins

Info

Publication number
SG10201600531TA
SG10201600531TA SG10201600531TA SG10201600531TA SG10201600531TA SG 10201600531T A SG10201600531T A SG 10201600531TA SG 10201600531T A SG10201600531T A SG 10201600531TA SG 10201600531T A SG10201600531T A SG 10201600531TA SG 10201600531T A SG10201600531T A SG 10201600531TA
Authority
SG
Singapore
Prior art keywords
antigen binding
binding proteins
pathogenic mycobacteria
capped lipoarabinomannan
mannose
Prior art date
Application number
SG10201600531TA
Inventor
Paul Anthony Macary
Conrad En Zuo Chan
Brendon John Hanson
Markus R Wenk
Original Assignee
Univ Singapore
Dso Nat Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore, Dso Nat Lab filed Critical Univ Singapore
Publication of SG10201600531TA publication Critical patent/SG10201600531TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
SG10201600531TA 2011-01-24 2012-01-25 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins SG10201600531TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161435396P 2011-01-24 2011-01-24

Publications (1)

Publication Number Publication Date
SG10201600531TA true SG10201600531TA (en) 2016-02-26

Family

ID=46581057

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201600531TA SG10201600531TA (en) 2011-01-24 2012-01-25 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
SG2013055256A SG192047A1 (en) 2011-01-24 2012-01-25 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013055256A SG192047A1 (en) 2011-01-24 2012-01-25 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins

Country Status (5)

Country Link
US (1) US9315566B2 (en)
EP (1) EP2668207A4 (en)
SG (2) SG10201600531TA (en)
WO (1) WO2012102679A1 (en)
ZA (1) ZA201305865B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US20150283374A1 (en) 2014-04-02 2015-10-08 Biotronik Se & Co. Kg Electric Feedthrough For Electromedical Implants, Electric Contact Element Comprising Such A Feedthrough, And Electromedical Implant
WO2016012449A1 (en) * 2014-07-22 2016-01-28 Tbdiadirect Ab Monoclonal antibody, method, kit and use
EP3414573B1 (en) * 2016-02-10 2023-11-08 Rutgers, the State University of New Jersey Novel anti-lam antibodies
US11796473B2 (en) 2017-07-12 2023-10-24 The Curators Of The University Of Missouri Detection of biomarkers using plasmonic gratings
US10830760B2 (en) 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
KR20190076897A (en) * 2017-12-22 2019-07-02 주식회사 수젠텍 Method for diagnosis of tuberculosis
EP3823670A4 (en) * 2018-07-19 2022-04-20 Rutgers, the State University of New Jersey Methods for dual detection and differentiation of infection by mycobactierum tuberculosis complex and nontuberculous mycobacteria
EP3845903A4 (en) * 2018-08-31 2021-11-24 FUJIFILM Corporation Immunochromatography kit, and method for detecting mycobacterium tuberculosis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2664073A1 (en) 1990-06-29 1992-01-03 Thomson Csf MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992014155A1 (en) 1991-02-12 1992-08-20 Dynagen, Inc. Monoclonal antibodies directed towards mycobacterial antigens
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5159012A (en) 1991-11-29 1992-10-27 Textile Rubber & Chemical Co., Inc. Process for the manufacture of polyurethane elastomers
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int Methods for producing transgenic non-human animals harboring a yeast artificial chromosome.
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE69513649T2 (en) 1994-04-14 2000-04-06 Adcock Ingram Ltd METHOD FOR DETECTING THE PRESENCE OF A MYCOBACTERIA SPECIES AND TEST SET, AND ANTIBODIES FOR USE IN THIS METHOD
DE69534601T2 (en) 1994-09-16 2006-08-03 The Scripps Research Institute, La Jolla USE OF ANTIBODIES TO PREVENT EFFECTS CAUSED BY GRAMPOSITIVE AND MYKO BACTERIA
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
DK0843961T3 (en) 1995-08-29 2007-05-21 Kirin Brewery Chimeric mouse and method of producing same
US6599691B1 (en) 1995-11-27 2003-07-29 The United States Of America As Represented By The Secretary Of The Navy Rapid immunoassay to detect infection with Mycobacterium tuberculosis
SE9600949D0 (en) 1996-03-12 1996-03-12 Stefan Svenson Method of diagnosing a mycobacterial disease and immunoassay kit
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6245331B1 (en) 1997-01-02 2001-06-12 New York Univ. Medical Center Early detection of mycobacterial disease
AU1749397A (en) 1997-01-17 1998-08-07 Trustees Of Boston University Mycobacterium antigens and methods for their detection
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6545130B2 (en) 1997-06-04 2003-04-08 Albert Einstein College Of Medicine Of Yeshiva University Monoclonal antibodies to mycobacterium tuberculosis and a modified ELISA assay
EP0921397A1 (en) 1997-12-08 1999-06-09 Kreatech Biotechnology B.V. A method for identifying a mycobacterium species
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001083525A2 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US6841159B2 (en) 2002-01-30 2005-01-11 The United States Of America As Represented By The Secretary Of The Navy Rapid lateral flow assay for determining exposure to Mycobacterium tuberculosis and other mycobacteria
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
KR20130065723A (en) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2004299053B2 (en) 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
EP1710584B1 (en) 2003-12-22 2010-07-07 Seikagaku Corporation Method of measuring lipoarabinomannan and application thereof
US7892557B2 (en) 2004-02-19 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
JP4948402B2 (en) 2004-07-20 2012-06-06 キーモゲン インコーポレイテッド Concentrated antibody for detecting mycobacterial infection, method of use, and diagnostic test using the same
CA2595074A1 (en) 2005-01-18 2006-07-27 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
US7638340B2 (en) 2005-06-22 2009-12-29 Seikagu Corporation Method of eliminating reactivity of lipoarabinomannan and application of the same
AU2006303998A1 (en) 2005-10-11 2007-04-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeted biocides
US7741475B2 (en) 2006-02-13 2010-06-22 Natural Products & Glycotechnology Research Institute, Inc. Synthesis of monovalent and polyvalent arabinans and mannose-capped arabinans of the protective cell-wall coat of mycobacterium tuberculosis
EP1933147B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Rapid immunochromatographic detection by amplification of the colloidal gold signal
US9175078B2 (en) * 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
CN101382548A (en) 2008-10-10 2009-03-11 中国人民解放军总医院第二附属医院 Tuberculosis antibody multi-antigen ELISA detecting kit and making method
CN101429238A (en) 2008-12-16 2009-05-13 深圳市菲鹏生物股份有限公司 Natural mycobacterium tuberculosis protein
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
WO2013180295A1 (en) 2012-06-01 2013-12-05 日本電信電話株式会社 Packet transfer processing method and packet transfer processing device
JP6071725B2 (en) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 Driving force control device for electric vehicles
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
EP2668207A1 (en) 2013-12-04
US20130309237A1 (en) 2013-11-21
EP2668207A4 (en) 2015-06-10
SG192047A1 (en) 2013-08-30
US9315566B2 (en) 2016-04-19
WO2012102679A1 (en) 2012-08-02
ZA201305865B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
IL267599B (en) St2 antigen binding proteins
HRP20180640T1 (en) Anti-b7-h3 antibody
IL259826A (en) Anti-alphabetatcr antibody
EP2681239B8 (en) Antigen binding proteins
HK1199042A1 (en) Cd27l antigen binding proteins cd27l
SG10201401681PA (en) Novel antigen binding proteins
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201305865B (en) Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
TWI563004B (en) Anti-hxcr1 antibody
IL226157A0 (en) Antigen binding proteins
SG11201503432SA (en) Monoclonal antibody against muramyl peptides
EP2769988A4 (en) Anti-gap43 antibody
EP2714074A4 (en) Anti-emr1 antibodies
GB201116342D0 (en) Antigen combinations